MicroLub: A novel microgel-based superlubricating formulation for fat replacement applications
MicroLub: A novel microgel-based superlubricating formulation for fat replacement applications
批准号:
EP/X03514X/1
负责人:
Anwesha Sarkar
金额:
$16.47万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Reducing fat in foods is a viable strategy to significantly decrease calorie intake and thus, fat replacer molecules are likely to be important in the race towards reversing the obesity crisis. The commercial fat replacer market is expected to considerably increase to 24 billion Euros by 2027, largely fueled by the growing public awareness for reduced-fat foods. However, the fat replacer industry faces severe technological challenges because the currently marketed fat replacers do not fully emulate the lubrication performance of full fat counterparts and thus fail to achieve consumers' expectations. The aim of the MicroLub project is to translate an innovative microgel-based technology with superlubricity developed in the context of the ERC project LubSat, towards the development of a more effective fat replacer ingredient. The technological innovation proposed includes deformable polypeptide-based microgels with grafted saccharides in a patchy heterogenous morphology. The exposed polypeptide region lead to a transient colloidal coating of the oral surfaces via hydrophobic interactions, whilst the grafted saccharides hydrogen bond with water molecules to create a microporous hydrated scaffold. This technology thus combines boundary and fluid film lubrication, unachieved by any fat replacement technologies available to date. Working through 4 work-packages, we will validate the techno-commercial feasibility of the formulation in close cooperation with experienced industrial partners and create the framework for potential licensing of this breakthrough technology to key industrial players. The expected outcomes aim to demonstrate the up-scaling feasibility and validation of technical performance against competition, filing a licensable patent, and developing a provisional business model that will allow us to build strategic alliances with selected industrial partners to take forward the commercialization of this technology and finally contribute towards reducing obesity
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.cocis.2023.101782
发表时间:
2023-12
期刊:
Current Opinion in Colloid & Interface Science
影响因子:
--
作者:
[A. Sarkar;Khalid Gul]
通讯作者:
A. Sarkar;Khalid Gul
PROTSENS Rethinking Alternative PROTein Extraction: Decoding SENsory-Protein Extraction Relationships
-
批准号:EP/Z000785/1
-
项目类别:Fellowship
-
资助金额:$26.26万
-
财政年份:2024
-
负责人:Anwesha Sarkar
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: